H.P. Acthar gel and cosyntropin review: Clinical and financial implications

P and T

Volumn 34, Issue 5, 2009, Pages 250-257

  Gettig, Jacob ^a   Cummings, Joseph P ^b   Matuszewski, Karl ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b University HealthSystem Consortium ^*  (United States)

^c Gold Standard   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CPP 109; METHYLPREDNISOLONE; NITRAZEPAM; PREDNISOLONE; PREDNISONE; PYRIDOXINE; TETRACOSACTIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ACQUIRED HEMOLYTIC ANEMIA; ADRENAL CORTEX; ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANKYLOSING SPONDYLITIS; ASPIRATION PNEUMONIA; ASTHMA; ATOPIC DERMATITIS; BERYLLIOSIS; BULLOUS DERMATITIS; BURSITIS; CARDITIS; CATARACT; CHORIORETINITIS; CHOROIDITIS; CLINICAL TRIAL; CONGENITAL HYPOPLASTIC ANEMIA; CONTACT DERMATITIS; DERMATOMYOSITIS; DIAGNOSTIC TEST; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG LABELING; ENTERITIS; EPICONDYLITIS; ERYTHEMA MULTIFORME; ERYTHROBLASTOPENIA; EXFOLIATIVE DERMATITIS; FOOD AND DRUG ADMINISTRATION; GOUT; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERCALCEMIA; HYPERTENSION; INFANTILE SPASM; IRIDOCYCLITIS; IRITIS; JUVENILE RHEUMATOID ARTHRITIS; KERATITIS; LEUKEMIA; LOEFFLER PNEUMONIA; LUNG TUBERCULOSIS; LYMPHOMA; MULTIPLE SCLEROSIS; MYCOSIS FUNGOIDES; OPTIC NEURITIS; OSTEOPOROSIS; PATIENT SELECTION; PEMPHIGUS; PLASMAPHERESIS; PRACTICE GUIDELINE; PROTEINURIA; PSORIASIS; PSORIATIC ARTHRITIS; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEBORRHEIC DERMATITIS; SERUM SICKNESS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYMPATHETIC OPHTHALMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; TENOSYNOVITIS; THROMBOCYTOPENIA; THYROIDITIS; TRICHINOSIS; TUBERCULOUS MENINGITIS; UNSPECIFIED SIDE EFFECT; UVEITIS; WEST SYNDROME;

EID: 78449250041     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. H.P. Acthar Gel, Repository Corticotropin Injection, package insert. Union City, CA: Questcor; revised January 2006. Available at: www.acthar.com/Pdf/Acthar-PI-pdf. Accessed June 2008.
2. Cortrosyn (cosyntropin) Injection, powder, for solution, package insert. Rancho Cucamonga, CA: Amphastar; September 2005. Available at: http://dailymed.nlm.nih.gov/dailymed/fda/ fdaDrugXsl.cfm?id=3164&type= display. Accessed June 2008.
3. Cosyntropin Injection 0.25 mg/mL, package insert. Princeton, NJ: Sandoz; 2008. Available at: www.fda.gov/cder/foi/label/2008/ 022028lbl.pdf. Accessed June 2008.
4. Sandoz launches cosyntropin liquid injection. March 2008. Princeton, NJ: Sandoz; Available at: www.us.sandoz.com/site/en/company/ news/pool/Cosyntropin- injection-launch.pdf. Accessed June 2008.
5. Caligor Rx ... since 1919 everything medical. New York. Available at: www.caligorrx.com/pages/1/index.htm. Accessed February 2009.
6. Questcor receives FDA action letter for H.P. Acthar Gel for treatment of infantile spasms. Union City, CA: Questcor; May 2007. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c= 89528&p=irol- newsArticle&ID=999781&highlight=. Accessed July 2008.
7. Drug Topics Red Book: Pharmacy's Fundamental Resource, 2007 Edition. Montvale, NJ: Thomson Medical Economics; 2007.
8. Benefit managers profit by specialty drug rights. The New York Times. April 19, 2008. Available at: www.nytimes.com/2008/04/ 19/business/19specialty. html?-r=1&oref=slogin&pagewanted= print. Accessed July 2008.
9. Questcor Board approves new strategy and business model for H.P. Acthar Gel. Union City, CA: Questcor; August 2007. Available at: http://phx.corporate- ir.net/phoenix.zhtml?c=89528&p=irol-newsArticle- print&ID= 1044912&highlight=. Accessed June 2008.
10. Dorin RI, Qualis CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003;139(3):194-204.
11. National Multiple Sclerosis Society. Who gets MS? Available at: www.nationalmssociety.org/about-multiple-sclerosis/who-getsms/ index.aspx. Accessed July 2008.
12. National Multiple Sclerosis Society. What is multiple sclerosis? Available at: www.nationalmssociety.org/about-multiple-sclerosis/ what-is-ms/index.aspx. Accessed July 2008.
13. Haines ST, Casto DT. Treatment of infantile spasms. Ann Pharmacother 1994;28:779-791.
14. MacKay M, Weiss S, Snead OC. Treatment of infantile spasms: An evidence-based approach. Int Rev Neurobiol 1999;49:157-184.
15. Drug details for H.P. Acthar Gel. Drugs@FDA Web site. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm? fuseaction= Search.DrugDetails. Accessed June 2008.
16. Schapiro RT. Medications used in the treatment of multiple sclerosis. Rehab Pharmacother 1999;10(2):437-446. (Pubitemid 29255094)
17. MacKay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: Medical treatment of infantile spasm. Report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668-1681. (Pubitemid 38661719)
18. National Institute for Clinical Excellence (NICE). Newer drugs for epilepsy in children. Technology appraisal; No. 79. London, U.K.: April 2004. Available at: www.guidelines.gov/summary/ pdf.aspx?doc-id=8643&stat= 1&string=newer+AND+drugs+AND+ep ilepsy+AND+children. Accessed July 2008.
19. Vigabatrin Mechanism of Action/Pharmacology. DRUGDEX Evaluations. In: Klasco RK (ed). MICROMEDEX Healthcare Series; December 2008. Available at: www.thomsonhc.com. Accessed February 2009.
20. Drug Topics Red Book, Pharmacy's Fundamental Resource, 2008 Edition. Montvale, NJ: Thomson Medical Economics; 2008.
21. Morrow T, Leist TP, Bainbridge J. Effective management of multiple sclerosis. Woodland Hills, CA: Advanstar Communications, Inc.; 2005.
22. Rai NR, Nunn-Thompson C. Agents for multiple sclerosis. Oak Brook, IL: University HealthSystem Consortium. Drug Monogr 2004;12:1-62.
23. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-971. (Pubitemid 19170424)
24. Goodkin DE. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med 1994;161: 292-298.
25. Hancock E, Osborne J. Treatment of infantile spasms. Cochrane Database Syst Rev 2002(2):D001770.
26. Riikonen R. Infantile spasms: Therapy and outcome. J Child Neurol 2004;19:401-404.
27. Ito M, Aiba H, Hashimoto K, et al. Low-dose ACTH therapy for West syndrome: Initial effects and long-term outcome. Neurology 2002;58:110-114. (Pubitemid 34041946)
28. Catalyst Pharmaceutical Partners begins enrollment for its U.S. phase II clinical trial of CPP-109 in patients with cocaine addiction. Coral Gables, FL: January 2008. Available at: http://ir.catalyst-pharma. com/releasedetail.cfm? ReleaseID=289632. Accessed July 2008.
29. Catalyst Pharmaceutical Partners, Inc., begins enrollment for U.S. phase II clinical trial of CPP-109 in patients with methamphet - amine addiction. June 2008. Available at: http://ir.catalystpharma. com/releasedetail.cfm?ReleaseID= 318907. Accessed July 2008.
30. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosatide at 14 days: A multicentre, randomised controlled trial. Lancet 2004;364:1773-1778. (Pubitemid 39488062)
31. Lux AL, Edward SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: A multicentre randomised trial. Lancet Neurol 2005; 4:712-717. (Pubitemid 41457286)
32. Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999;21(7):461-467. (Pubitemid 29428075)
33. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study. Epilepsia 1997;38(12):1270-1274. (Pubitemid 28007515)
34. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotrophin (ACTH) versus prednisone for infantile spasms: A prospective, randomized, blinded study. Pediatrics 1996;97(3):375-379. (Pubitemid 26076265)
35. Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994;124:803-806.
36. Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms: Comparative trial of nitrazepam and corticotropin. Arch Neurol 1986; 43:1107-1110. (Pubitemid 17174436)
37. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs. prednisone therapy in infantile spasms. J Pediatr 1983;103:641-645. (Pubitemid 13011986)
38. Phase II randomized study of early surgery vs. multiple sequential antiepileptic drug therapy for infantile spasms refractory to standard treatment. Clinicaltrials.gov. Revised June 2005. Available at: www.clinicaltrials.gov/ct2/show/NCT00004758?cond= infantile+spasms&rank=5. Accessed July 2008.
39. Search of clinicaltrials.gov for adrenocorticotropin OR adreno-corticotrophic hormone OR tetracosatide OR cosyntropin. Available at: www.clinicaltrials.gov. Accessed July 2008.
40. Urgent Product Alert: H.P. Acthar Gel. Union City, CA: Questcor; July 2007. Available at: www.acthar.com/Pdf/Physician.pdf. Accessed July 2008.
41. Questcor amends agreement with U.S. Acthar distributor. Union City, CA: Questcor; April 2008. Available at: http://phx.corporateir. net/phoenix.zhtml?c= 89528&p=irolnewsArticle& ID=1136159&highlight=. Accessed July 2008.
42. Acthar Patient Support and Reimbursement Program. Available at: www.acthar.com/getting-started. Union City, CA: Questcor; 2009. Accessed April 2009.
43. How to access H.P. Acthar Gel (ACTH) for treatment of infantile spasms. Silver Spring, MD: Tuberous Sclerosis Alliance. Available at: www.tsalliance.org/pages.aspx?content=425. Acthar Support & Access Program (ASAP). Revised June 2007. Accessed April 2009.
44. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36(6):1937-1949.
45. Questcor resubmits supplemental new drug application to FDA for H.P. Acthar Gel for treatment of infantile spasms. Union City, CA: Questcor; December 2008. Available at: http://phx.corporateir. net/phoenix.zhtml?c=89528&p= irol-newsArticle&ID=1231721 &highlight=. Accessed February 2009.